|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global Cancer Statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Macdonald JS, Smalley SR, Benedetti J,
Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA,
Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after
surgery compared with surgery alone for adenocarcinoma of the
stomach or gastroesophageal junction. N Engl J Med. 345:725–730.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Margulis V, Lotan Y and Shariat SF:
Survivin: A promising biomarker for detection and prognosis of
bladder cancer. World J Urol. 26:59–65. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pennati M, Folini M and Zaffaroni N:
Targeting survivin in cancer therapy. Expert Opin Ther Targets.
12:463–476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kato J, Kuwabara Y, Mitani M, Shinoda N,
Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and
Fujii Y: Expression of survivin in esophageal cancer: Correlation
with the prognosis and response to chemotherapy. Int J Cancer.
95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang LQ, Wang J, Jiang F, Xu L, Liu FY
and Yin R: Prognostic value of survivin in patients with non-small
cell lung carcinoma: A systematic review with meta-analysis. PLoS
One. 7:e341002012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krieg A, Werner TA, Verde PE, Stoecklein
NH and Knoefel WT: Prognostic and clinicopathological significance
of survivin in colorectal cancer: A meta analysis. PLoS One.
8:e653382013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hingorani P, Dickman P, Garcia-Filion P,
White-Collins A, Kolb EA and Azorsa DO: BIRC5 expression is a poor
prognostic marker in Ewing sarcoma. Pediatr Blood Cancer. 60:35–40.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carter BZ, Qiu Y, Huang X, Diao L, Zhang
N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, et al:
Survivin is highly expressed in CD34(+)38(−) leukemic
stem/progenitor cells and predicts poor clinical outcomes in AML.
Blood. 120:173–180. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vallböhmer D, Drebber U, Schneider PM,
Baldus S, Bollschweiler E, Brabender J, Warnecke-Eberz U, Mönig S,
Hölscher AH and Metzger R: Survivin expression in gastric cancer:
Association with histomorphological response to neoadjuvant therapy
and prognosis. J Surg Oncol. 99:409–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jamieson NB, Carter CR, McKay CJ and Oien
KA: Tissue biomarkers for prognosis in pancreatic ductal
adenocarcinoma: A systematic review and meta-analysis. Clin Cancer
Res. 17:3316–3331. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Steck PA, Pershouse MA, Jasser SA, Yung
WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T,
et al: Identification of a candidate tumour suppressor gene, MMAC1,
at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat Genet. 15:356–362. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ngeow J, Sesock K and Eng C: Clinical
implications for germline PTEN spectrum disorders. Endocrinol Metab
Clin North Am. 46:503–517. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Correia NC, Girio A, Antunes I, Martins LR
and Barata JT: The multiple layers of non-genetic regulation of
PTEN tumour suppressor activity. Eur J Cancer. 50:216–225. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bermúdez Brito M, Goulielmaki E and
Papakonstanti EA: Focus on PTEN regulation. Front Oncol. 5:1662015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Que WC, Qiu HQ, Cheng Y, Liu MB and Wu CY:
PTEN in kidney cancer: A review and meta-analysis. Clin Chim Acta.
480:92–98. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hill R, Calvopina JH, Kim C, Wang Y,
Dawson DW, Donahue TR, Dry S and Wu H: PTEN loss accelerates
KrasG12D-induced pancreatic cancer development. Cancer Res.
70:7114–7124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Han F, Hu R, Yang H, Liu J, Sui J, Xiang
X, Wang F, Chu L and Song S: PTEN gene mutations correlate to poor
prognosis in glioma patients: A meta-analysis. Onco Targets Ther.
9:3485–3492. 2016.PubMed/NCBI
|
|
20
|
Yazdani Y, Farazmandfar T, Azadeh H and
Zekavatian Z: The prognostic effect of PTEN expression status in
colorectal cancer development and evaluation of factors affecting
it: Mir-21 and promoter methylation. J Biomed Sci. 23:92016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Golmohammadi R, Rakhshani MH, Moslem AR
and Pejhan A: Prognostic role of PTEN gene expression and length of
survival of breast cancer patients in the north east of Iran. Asian
Pac J Cancer Prev. 17:305–309. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang HM, Fan TT, Li W and Li XX:
Expressions and significances of ttf-1 and PTEN in early
endometrial cancer. Eur Rev Med Pharmacol Sci. 21 (Suppl
3):S20–S26. 2017.
|
|
23
|
Giles KM, Rosenbaum BE, Berger M, Izsak A,
Li Y, Illa Bochaca I, Vega-Saenz de Miera E, Wang J, Darvishian F,
Zhong H and Osman I: Revisiting the clinical and biologic relevance
of partial PTEN loss in melanoma. J Investig Dermatol. 139:430–438.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morotti A, Panuzzo C, Crivellaro S, Carra
G, Torti D, Guerrasio A and Saglio G: The role of PTEN inmyeloid
malignancies. Hematol. Rep. 7:58442015.
|
|
25
|
Gu Y, Jin S, Wang F, Hua Y, Yang L, Shu Y,
Zhang Z and Guo R: Clinicopathological significance of PI3K, Akt
and survivin expression in gastric cancer. Biomed Pharmacother.
68:471–475. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yusup A, Huji B, Fang C, Wang F, Dadihan
T, Wang HJ and Upur H: Expression of trefoil factors and TWIST1 in
colorectal cancer and their correlation with metastatic potential
and prognosis. World J Gastroenterol. 23:110–120. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lins RR, Oshima CT, Oliveira LA, Silva MS,
Mader AM and Waisberg J: Expression of E-cadherin and WNT pathway
proteins Betacatenin, APC, TCF-4 and Survivin in gastric
adenocarcinoma: Clinical and pathological implication. Arq Bras Cir
Dig. 29:227–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deng H, Wu RL, Zhou HY, Huang X, Chen Y
and Liu LJ: Significance of Survivin and PTEN expression in full
lymph node-examined gastric cancer. World J Gastroenterol.
12:1013–1017. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Contis J, Lykoudis PM, Goula K, Karandrea
D and Kondi-Pafiti A: Survivin expression as an independent
predictor of overall survival in pancreatic adenocarcinoma. J
Cancer Res Ther. 14 (Suppl):S719–S723. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xia H, Chen S, Huang H and Ma H: Survivin
over-expression is correlated with a poor prognosis in esophageal
cancer patients. Clin Chim Acta. 446:82–85. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li S, Wang L, Meng Y, Chang Y, Xu J and
Zhang Q: Increased levels of LAPTM4B, VEGF and survivin are
correlated with tumor progression and poor prognosis in breast
cancer patients. Oncotarget. 8:41282–41293. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bury J, Szumiło J, Dąbrowski A, Ciechański
A, Śliwińska J and Wallner G: Vascular endothelial growth factor
and survivin immunostaining in gastric adenocarcinoma. Pol Przegl
Chir. 84:341–347. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang ZN, Xu HM, Jiang L, Zhou X, Lu C and
Zhang X: Expression of survivin in primary and metastatic gastric
cancer cells obtained by laser capture microdissection. World J
Gastroenterol. 10:3094–3098. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen J, Li T, Liu Q, Jiao H, Yang W, Liu X
and Huo Z: Clinical and prognostic significance of HIF-1a, PTEN,
CD44v6, and survivin for gastric cancer: A meta-analysis. PLoS One.
9:e918422014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Milella M, Falcone I, Conciatori F, Cesta
Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S,
Cognetti F and Ciuffreda L: PTEN: Multiple functions in human
malignant tumors. Front Oncol. 5:242015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bazzichetto C, Conciatori F, Pallocca M,
Falcone I, Fanciulli M, Cognetti F, Milella M and Ciuffreda L: PTEN
as a prognostic/predictive biomarker in cancer: An unfulfilled
promise? Cancers (Basel). 11:4352019. View Article : Google Scholar
|
|
37
|
Li Y, Cui J, Zhang CH, Yang DJ, Chen JH,
Zan WH, Li B, Li Z and He YL: High-expression of DJ-1 and loss of
PTEN associated with tumor metastasis and correlated with poor
prognosis of gastric carcinoma. Int J Med Sci. 10:1689–1697. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu X, Qin X, Fei M, Hou W, Greshock J,
Bachman KE, Kang J and Qin Y: Loss and reduced expression of PTEN
correlate with advanced-stage gastric carcinoma. Exp Ther Med.
5:57–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bai ZG, Ye YJ, Shen DH, Lu YY, Zhang ZT
and Wang S: PTEN expression and suppression of proliferation are
associated with Cdx2 overexpression in gastric cancer cells. Int J
Oncol. 42:1682–1691. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lu D, Qian J, Yin X, Xiao Q, Wang C and
Zeng Y: Expression of PTEN and survivin in cervical cancer:
Promising biological markers for early diagnosis and prognostic
evaluation. Brit J Biomed Sci. 69:143–146. 2012. View Article : Google Scholar
|
|
41
|
Wu ZX, Song TB, Li DM, Zhang XT and Wu XL:
Overexpression of PTEN suppresses growth and induces apoptosis by
inhibiting the expression of survivin in bladder cancer cells.
Tumour Biol. 28:9–15. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jin M, Li C, Zhang Q, Xing S, Kan X and
Wang J: Effects of aspirin on proliferation, invasion and apoptosis
of Hep-2 cells via the PTEN/AKT/NF-κB/survivin signaling pathway.
Oncol Lett. 15:8454–8460. 2018.PubMed/NCBI
|
